首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   57679篇
  免费   4685篇
  国内免费   1204篇
耳鼻咽喉   789篇
儿科学   605篇
妇产科学   534篇
基础医学   3778篇
口腔科学   877篇
临床医学   9208篇
内科学   7273篇
皮肤病学   578篇
神经病学   3015篇
特种医学   1208篇
外国民族医学   7篇
外科学   6215篇
综合类   9900篇
现状与发展   6篇
一般理论   1篇
预防医学   6898篇
眼科学   468篇
药学   5386篇
  114篇
中国医学   4155篇
肿瘤学   2553篇
  2024年   121篇
  2023年   1276篇
  2022年   1840篇
  2021年   3051篇
  2020年   2941篇
  2019年   2455篇
  2018年   2590篇
  2017年   2272篇
  2016年   2476篇
  2015年   2285篇
  2014年   5114篇
  2013年   4831篇
  2012年   4304篇
  2011年   4220篇
  2010年   3182篇
  2009年   2651篇
  2008年   2386篇
  2007年   2354篇
  2006年   1909篇
  2005年   1635篇
  2004年   1336篇
  2003年   1218篇
  2002年   892篇
  2001年   821篇
  2000年   652篇
  1999年   564篇
  1998年   444篇
  1997年   387篇
  1996年   376篇
  1995年   370篇
  1994年   332篇
  1993年   257篇
  1992年   201篇
  1991年   164篇
  1990年   186篇
  1989年   149篇
  1988年   119篇
  1987年   115篇
  1986年   95篇
  1985年   177篇
  1984年   152篇
  1983年   108篇
  1982年   124篇
  1981年   81篇
  1980年   91篇
  1979年   39篇
  1978年   54篇
  1977年   40篇
  1976年   33篇
  1974年   28篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
目的探讨白芷酒炖前后对挥发性成分的影响。方法采用顶空固相微萃取技术(HS-SPME)结合气相色谱-质谱法(GC-MS)对白芷酒炖前后挥发性成分及其相对百分含量进行对比分析。结果从白芷生品中初步检测出53个峰,鉴定出36个成分;从白芷酒炖中检测出32个峰,鉴定出26个成分;与生品成分比较,酒炖白芷中有22种成分未测到,但新增了12种成分,表明酒炖白芷中的挥发性成分的组成和含量均发生了变化。结论白芷酒炖后由于受热及辅料黄酒的作用使挥发性成分的种类及含量发生了明显变化,并存在成分转化,本研究为白芷酒炖的炮制机理及其在都梁丸中应用的物质基础研究提供了科学依据。  相似文献   
92.
IntroductionTo disentangle the association between impulsive and compulsive behaviors (ICBs), health-related quality of life (HRQOL), satisfaction with life (SwL), and caregiver distress in dyads of people with Parkinson's disease (PwP) and caregivers.MethodsData used in this study were obtained from the ongoing Norwegian ParkWest study, a population-based longitudinal cohort study of the incidence, neurobiology and prognosis of PD in Western Norway. One hundred and one dyads of PwP free of dementia and their caregivers were included 5 years after PD diagnosis and inclusion in the ParkWest study. Standardized clinical rating scales were used to evaluate ICBs, HRQOL, SwL and caregiver distress.ResultsOf 101 PwP-caregiver dyads, self-reported ICBs were seen in 33% of PwP and only caregiver-reported ICBs in 12% of PwP. PwP-reported ICBs were associated with poorer HRQOL and SwL, whereas ICBs reported by caregivers only were associated with increased caregiver distress, but not poorer HRQOL or SwL in PwP.ConclusionsICBs have adverse effects on HRQOL, SwL and caregiver distress. These findings underpin the need for proper identification and management of ICBs in PwP.  相似文献   
93.

Background

Most elderly trauma patients suffer blunt head injury and many utilize antithrombotic (AT) medications. The utility of delayed CT-head (D-CTH) in neurologically intact elderly patients using AT who have an intracranial hemorrhage (ICH) on presentation is unknown. We hypothesized that D-CTH would not alter clinical management and aimed to evaluate the role of D-CTH in this population.

Methods

A retrospective cohort study was performed. Patients ≥65 years sustaining blunt head injuries from January 2010 to July 2017 were identified using our level 1 trauma center database. AT-patients presenting with ICH who underwent D-CTH were included. Patients with worsened ICH were compared to those with stable to improved ICH on D-CTH. AT-patients were compared to a cohort of non-AT patients. Fisher’s Exact and Mann-Whitney U tests were utilized and a power analysis conducted.

Results

137?A?T and 34 non-AT patients were identified. There was no difference in hemorrhage progression or appearance of new ICH. No patient had a change in management from D-CTH in either cohort. AT-patients were slightly older (p?<?0.001), but cohorts were otherwise similar.50 AT-patients with worsened ICH were compared to 87 with stable ICH. There was no difference in cohort demographics. Hemorrhage progression did not vary with type of AT used but did increase if multiple types of synchronous ICH were present (p?<?0.001).

Conclusions

Our data supports abstaining from routine D-CTH of elderly ICH patients with an intact neurologic examination who are utilizing aspirin, clopidogrel or warfarin. Conclusions cannot be drawn regarding new oral anticoagulants (NOACs) given low enrollment. Further multicenter study is required to provide adequate power and detect small levels of management change.  相似文献   
94.
Hepatitis C is a global public health problem, and Pakistan is the second largest country in the globe with highest prevalence rate of hepatitis C virus (HCV). Until 2014, pegylated interferon (PEG-IFN) plus ribavirin (RBV) has been the standard therapy for HCV, however, owing to its adverse side effects and very low sustained virologic response (SVR) rates therapeutics trend is shifted toward direct-acting antivirals. Tripartite motif containing 22 (TRIM22) is a dynamic antiviral protein that can inhibit multiple viruses in vivo. Expression of TRIM22 mRNA has been linked to outcome of PEG-IFN and ribavirin therapy, where its higher expression leads to rapid virus clearance. However, in terms of therapy with direct-acting antiviral (DAA) or double DAA, impact of TRIM22 expression is largely unknown. These new drugs show more than 90% of SVR rates and lesser side effects and have proven to be better than IFN therapy. Endogenous IFN system suppresses various pathogens through the induction of antiviral effectors termed as interferon-stimulating genes (ISGs). We have studied the expression levels of one of these antiviral effectors, TRIM22 in response to sofosbuvir (SOF) and daclatasvir (DAC) in combination with RBV, using quantitative PCR in the peripheral blood mononuclear cells (PBMCs) of HCV-infected patients. We have observed sustained virus clearance in more than 90% of patients treated with DAA and double DAA and have seen the expression of TRIM22 to be higher in patients who attained SVR as compared to the untreated patients. We have also observed downregulation of TRIM22 in patients who failed to attain rapid virus clearance, and upregulation in those who achieved rapid clearance of virus. Genetic factors that determine the lower TRIM22 expression in these patients are needed to be explored that may also play a role in lower response to anti-HCV therapy. Endogenous IFN system and effects of antiviral proteins in response to DAA therapy is needed to be studied in order to better understand the host response toward these drugs to make them more effective.  相似文献   
95.
余华伟 《中外医疗》2016,(20):79-80
目的:探讨老年股骨粗隆间骨折手术时机对临床预后结局的影响。方法整群选取2015年1月—2016年1月该院收治的老年股骨粗隆间骨折患者68例为研究对象。根据患者手术时间将其分为A组与B组, A组32例,B组36例,观察两组患者不同年龄术后30 d、1年的死亡情况。结果两组患者术后30d、1年死亡率比较差异无统计学意义,P>0.05;但A组、B组患者中超过80岁的患者术后1年死亡率明显低于80岁以下年龄患者,P<0.05,差异具有统计学意义。结论年龄超过80岁的老年股骨粗隆间骨折患者术后1年死亡率相对较高。  相似文献   
96.
97.
目的通过MRI技术观察偏瘫患者肩疼痛腋囊形态变化,为影像诊断提供依据。方法对47例偏瘫性肩疼痛患者(疼痛组)和47例正常肩部(对照组),运用MRI技术对肩关节腋囊进行测量,观察腋囊下肱盂韧带信号。结果偏瘫性肩疼痛的腋囊厚度(4.1±1.45)mm,高于对照组。腋囊腔高度(8.70±1.80)mm,腋囊腔宽度(4.31±0.56)mm,小于对照组。偏瘫性肩痛下肱盂韧带呈高信号出现率达21%,腋囊厚度与VAS呈正相关,与肩关节外展外旋呈负相关。结论脑中风中后期肩周炎是引起偏瘫性肩疼痛患者的常见原因,腋囊厚度是限制肩关节活动度的重要因素。  相似文献   
98.
目的:探讨分析肿瘤合并新冠病毒感染患者情况并提出自己的思考与建议。方法:通过统计2020年1月至2020年3月期间纳入的313名本院肿瘤科在新冠疫情期间肿瘤合并感染新冠肺炎患者情况,汇总临床资料,分析患者肺部影像学特点,总结肿瘤合并新冠肺炎病毒感染患者临床特征、预后及转归等,并提出自己建议。结果:科室总共313名患者住院,5名新冠感染患者,新冠病毒肺炎发生率为1.6%,这比之前所报道的武汉市新冠病毒普通人群发生率0.37%要高接近3倍,肿瘤合并新冠患者死亡率接近20%。结论:对于疫情结束初期病房应尽量减少患者非必要往返医院次数,实行肿瘤患者分层管理,加强轻症患者随访,线上管理等;而对于住院患者,则采取缓冲分诊模式,做好病房消毒隔离以及管理,避免感染,减少肿瘤病房新型冠状病毒爆发概率。  相似文献   
99.
目的 阻塞性睡眠呼吸暂停低通气综合征(OSAHS)是耳鼻咽喉科的一种常见病,儿童发病率呈上升趋势,调查显示儿童OSAHS发生率为4%~5%,2~6岁是发病的高峰期。OSAHS不仅严重影响儿童的睡眠质量,还会引起儿童生长发育迟缓、智力缺陷等一系列不良反应,OSAHS患儿的主要病因是扁桃体和/或腺样体肥大,因此最有效的治疗方法是扁桃体切除术和腺样体切除术。而扁桃体和腺样体是儿童淋巴组织系统的重要组成部分,在机体的防御和保护功能中发挥着重要作用。手术治疗OSAHS是否影响儿童的免疫功能目前存在争议。一些学者认为扁桃体切除和腺样体切除后儿童的免疫力降低,而另一些学者认为OSAHS儿童的免疫力在手术后保持不变,甚至比手术前有所提高。本文就儿童OSAHS手术前后免疫指标的变化作一综述。  相似文献   
100.
外感之邪从口鼻、皮毛侵袭人体,肺卫首先受邪。在外感病初期,肺卫失宣是病机的关键,治疗应重在宣通肺卫。外感风寒邪气,寒邪直接损伤卫阳,郁遏肺气,治当辛温解表。外感风热邪气,阳邪郁遏气机,损伤津液,易化燥化火,甚则内陷生变,治当辛凉解表。湿热邪气从口鼻、皮毛而入,初起即表现为卫气同病,治当宣化表里湿热。燥气为病,易伤肺脏、耗津液,与热相合则易化热化火,而成温燥,治宜辛凉甘润。外感热病初起,六淫邪气侵袭肺卫,气机郁滞,进而津停成饮、成痰;气有余便是火,郁滞之气化燥化火,甚则动血。治疗总则为宣通气机,此即"透法"之运用。故在外感热病初起的治疗中,贵在把握气机状态,让肺卫之气宣畅,正气宣布,则邪气潜消。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号